WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment for hospitalized COVID-19 patients
The World Health Organization announced that it would discontinue its trial of hydroxychloroquine and lopinavir/ritonavir treatments in the fight against COVID-19.
The WHO's Solidarity Trial was established to find effective treatments for the coronavirus in hospitalized patients.
But the organization said that the recommendation was made to end the trials after evidence showed that neither of the drugs reduced the mortality rate of hospitalized COVID-19 patients, compared to standard-of-care treatments.
The WHO notes that the decision only applies to conduct from the Solidarity trials and does not affect possible evaluations in other studies of the drugs.